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Abstract
Diabetic macular oedema (DMO) is a leading cause of vision loss in the working-age population worldwide. Corticosteroid drugs have been 
demonstrated to inhibit the expression of both the vascular endothelial growth factor (VEGF) gene and other anti-inflammatory mediators, 
such as prostaglandins. Triamcinolone, fluocinolone and dexamethasone are the main steroids that have been studied for the treatment 
of macular oedema. Over the last few years, several studies have suggested an important role for dexamethasone in the management of 
DMO. The dexamethasone intravitreal implant (DEX implant) (Ozurdex®; Allergan, Inc., Irvine, CA) is a novel approach approved by the US 
Food and Drug Administration (FDA) and by the EU for the intravitreal treatment of macular oedema after branch or central retinal vein 
occlusion, and for the treatment of non-infectious uveitis affecting the posterior segment of the eye. We reviewed manuscripts that had 
investigated the pharmacokinetics, efficacy and safety of the DEX implant regarding DMO treatment.
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Diabetic retinopathy (DR) is the leading cause of blindness among 
working-aged adults around the world.1 Despite the significance of this 
problem, and the rising prevalence of diabetes, notably in emerging 
Asian countries, such as India and China,2,3 there are few precise 
contemporary estimates of the worldwide prevalence of DR, particularly 
severe vision-threatening stages of the disease, including proliferative 
DR (PDR) and diabetic macular oedema (DMO). 
Yau et al. provided a global estimate of the prevalence of DR and the severe 
stages of DR (PDR, DMO) using individual-level data from population-
based studies worldwide.4 On the basis of the data from all 35 studies on 
more than 20,000 participants with diabetes, they estimated that among 
individuals with diabetes, the overall prevalence of any DR was 34.6 %, 
PDR was 7.0 %, DMO was 6.8 % and VTDR was 10.2 %.
DR is a highly specific vascular complication of both type 1 and 2 diabetes, 
with prevalence strongly related to the duration of diabetes.5 In addition to 
the duration of diabetes, factors that increase the risk of, or are associated 
with, retinopathy include chronic hyperglycaemia,6 nephropathy7 and 
hypertension.8 Intensive diabetes management with the goal of achieving 
near-normoglycemia has been shown in large prospective randomised 
studies to prevent and/or delay the onset and progression of DR.9–11 Lowering 
blood pressure has been shown to decrease the progression of retinopathy.12
DMO is a frequent complication of DR and the most common cause of 
vision loss in patients with diabetes. Left untreated, up to 33 % of patients 
with DMO will experience moderate vision loss.13 Laser photocoagulation 
has been considered, for a long time, as the main treatment option for 
DMO, based on the results of the Early Treatment Diabetic Retinopathy 
Study (ETDRS) clinical trial.14 Focal laser treatment reduced the risk of 
moderate visual loss in patients with DMO by 50 %.15 
In more recent studies that involved only patients with DMO-associated 
vision loss, repeated applications of focal/grid laser photocoagulation 
treatment resulted in at least a 10-letter improvement in visual acuity 
in 28–32 % of patients, but 13–19 % of patients lost at least 10 letters 
in visual acuity.16–17
In DMO, vascular leakage from dilated hyperpermeable capillaries 
and microaneurysms leads to accumulation of extracellular fluid 
in the macula. Inflammation has a key role in the pathogenesis and 
maintenance of DMO.18–20 The pathological processes leading to MO 
involve numerous inflammatory cells, cytokines, growth factors 
and intercellular adhesion molecules, which are associated with 
increased vascular permeability, breakdown of the blood–retinal 
barrier, remodelling of the extracellular matrix and upregulation of 
proangiogenic factors.19–22
Actually, studies suggest that the expression of vascular endothelial 
growth factor (VEGF) is elevated in DMO.22–24 This has recently been 
confirmed by randomised clinical trials, which led to considering 
intravitreal anti-VEGF as a valuable treatment option for DMO.25,26 
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Nevertheless, some patients can be refractory to both macular laser 
photocoagulation and intravitreal anti-VEGF treatment. Indeed, MO 
refractory to laser photocoagulation remains the most prevalent cause of 
untreatable vision loss in diabetes.27–28 The lack of an effective therapeutic 
solution accounts for the range of interventions proposed, prior to the 
appearance of the dexamethasone intravitreal implant (DEX implant). 
These included intraocular delivery of corticosteroids and anti-VEGF 
antibodies, as well as the surgical alternative of vitrectomy with or 
without removal of the internal limiting membrane (ILM).29–33
Dexamethasone is a potent corticosteroid and suppresses inflammation 
by inhibiting oedema, fibrin deposits, capillary leakage and phagocytic 
migration.34 Glucocorticoids such as dexamethasone exert their 
anti-inflammatory effects by influencing multiple signal transduction 
pathways, including VEGF.34–37 By binding to cytoplasmic glucocorticoid 
receptors, corticosteroids in high doses increase the activation of 
anti-inflammatory genes, whereas at low concentrations, they 
have a role in the suppression of activated inflammatory genes.35–38 
Therefore, a drug-release profile that consists of an initial phase 
of high concentration of dexamethasone, followed by a second 
phase of lower concentration, may continue to contribute to the 
anti-inflammatory action of dexamethasone for the duration of 
the implant. 
The dexamethasone implant (Ozurdex®; Allergan, Inc., Irvine, CA) is 
a novel approach approved by the US Food and Drug Administration 
(FDA) and by the EU for the intravitreal treatment of MO after 
branch or central retinal vein occlusion, and for the treatment of 
non-infectious uveitis affecting the posterior segment of the eye.39 
However, there is evidence for efficacy in multiple clinical situations, 
including DMO MO associated with uveitis or Irvine-Gass syndrome, 
DMO in vitrectomised eyes, persistent MO and non-infectious 
vitritis.23–30,39–46 Compared with published data addressing other routes 
of administration of dexamethasone analogues, several results 
demonstrate a few advantages of this implant (see Table 1). 
Implantable Drug-delivery Systems
Therapeutic levels, minimum inhibitory concentrations, pharmacokinetics, 
the blood–brain barrier and patient adherence are just some of 
the obstacles associated with the traditional topical and systemic 
administrations of medicine.47 Even intravitreal injections, long favoured 
for posterior segment disease, fall short. In fact, molecules injected into 
the vitreous have a brief intraocular half-life.48
Recently, intravitreal sustained delivery-drug devices were introduced 
to allow corticosteroids to be delivered in a slow, sustained manner to 
optimise the efficacy and safety of treatment and reduce the number 
of intravitreal injections a patient may require. 49–51
In accordance, implants have already proved themselves in inflammatory 
diseases.50 Actually, a wide array of chronic illnesses stand to gain from 
implant delivery, which is advantageous, given the ageing population of 
most societies.51,52
Reservoir Implants
Although reservoir implants require surgical placement or replacement, 
simplicity, longevity and steady-state pharmacokinetics are their benefits. 
Vitrasert. Approved in early 1996 for the treatment of AIDS-related 
cytomegalovirus retinitis, this implantable was a form of ganciclovir.53 
There were limited ocular complications and the efficacy far 
exceeded the standard of care, which was the same drug, ganciclovir, 
administered intravenously. Surgically implanted through a 5.5 mm pars 
plana incision, Vitrasert lasts 5 to 8 months. With the advent of more 
potent combination therapies for HIV infection, however, opportunistic 
infections were more easily controlled or prevented, and so the need 
for Vitrasert waned.54,55 
Retisert. The next generation of implant, Retisert, achieved even better 
targeted delivery and duration.56,57 Sutured to the sclera after surgical 
implantation through a 3.5 mm pars plana incision, Retisert releases 
fluocinolone acetonide and lasts about 30 months.58 However, that 
duration comes with the downside of ocular side effects. Although FDA-
approved in 2005 for non-infectious uveitis after achieving dramatically 
reduced recurrence of uveitis, the toxicities were considered too much 
for patients with DMO. Studies emphasised that the risk of cataract 
was upward of 90  % with Retisert.58,59 On the other hand, the risk of 
glaucoma is about 50 % with a Retisert implant, and about a third of 
those patients end up needing surgery because the glaucoma cannot 
be controlled with medication alone.
Iluvien. This is an injectable, non-degradable intravitreal implant 
for the treatment of DMO.60,61 Iluvien is designed to release the drug 
fluocinolone acetonide for up to 3 years.61,63 The device is small enough 
to be injected into the back of the eye with a 25-gauge needle, creating 
a self-sealing hole. Due its non-biodegradability, it is necessary to 
surgically remove the implant 3 years later. Recently, Iluvien was 
approved for DMO in several European countries, receiving marketing 
authorisation in the UK, Austria, France, Germany, Portugal and Spain. 
These marketing authorisations followed a positive outcome of the 
European Decentralised Procedure.
Biodegradable Implants
Although biodegradable implants are newer, they offer the prospect 
of certain benefits over reservoir systems, such as the lack of need 
for removal and a reduced potential for ocular toxicity. Biodegradable 
implants are more easily tailored by modifying polymer chemistry to 
change release rates and accommodate different drugs.
Surodex. The first sustained-release biodegradable steroid implant, 
this device was placed behind the iris for postoperative inflammation 
after cataract surgeries.64 A market did not materialise, however, 
because Medicare would not reimburse for its placement during 
cataract surgery.
Ozurdex. Inserted surgically in the operating room or with a special 
injector, this device secured FDA approval for Allergan in June of 
2009 for MO caused by vein occlusion.39 Called Posurdex during 
testing, the FDA required a name change for the version distributed 
in the US. Now called Ozurdex, this implant is a biodegradable 
copolymer in pellet form that hydrolyses to lactic and glycolic acids, 
releasing 700 µg over 6 months. Because it is a more water-soluble 
steroid than triamcinolone or fluocinolone acetonide, Ozurdex may 
be able to control several retinal diseases without causing as many 
ocular complications.39–52
Dexamethasone Intravitreal Implant 
Dexamethasone has the highest relative strength of any corticosteroid 
used in ophthalmic practice, with an anti-inflammatory activity that 
is sixfold greater than that of triamcinolone and 30-fold greater than 
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Table 1: Clinical Studies Published Up to Now, Regarding Dexamethasone Intravitreal  
Implant in Diabetic Macular Oedema
Author,  Purpose Study Design Outcomes Type of DMO Duration  Number Results of Eyes
Year (Reference)   Measures   of Study 
Dutra DEX implant Retrospective FT Refractory 6 months 58 Both FT and BCVA improved from 
Medeiros for DMO interventional BCVA    baseline by 1 month. The 
201483  case series     improvement remained statistically 
       significant throughout the 6-month 
       study. The peak effectiveness was 
       seen at 3 months, when FT had 
       decreased by 37 %, and BCVA 
       improved to 0.44±0.27 logMAR
Pacella DEX implant Prospective FT Refractory 6 months 20 Substantial improvement in BCVA 
201382 for DMO interventional BCVA    and FT from day 3. The peak 
  case series Retinal    efficacy of the implant appears to be 
   structure    reached at month 1 through to 
       month 3. It then slowly decreases 
       from month 4 to 6
Callanan DEX implant Randomised, BCVA Diffuse DMO 12 months 253 No significant between-group 
PLACID with laser controlled, Fluorescein    difference at month 12.  
Study Group photocoagulation multicentre, leakage    Significantly greater improvement 
201379 compared double-masked     in BCVA up to 9 months occurred 
 with laser      in patients with diffuse DMO treated 
 alone for DMO      with DEX implant plus laser, than in 
       patients treated with laser alone
Rishi DEX implant Retrospective FT Refractory 5 months 18 The maximum reduction in FT was 
201281 for DMO interventional BCVA    seen at month 1 followed by 
  case series     reappearance of DMO at month 4.  
       The peak effect of the drug was  
       between 1 and 4 months
Zucchiatthi DEX implant Retrospective FT Refractory 6 months 9 Improvement in BCVA and FT as 
201280 for DMO interventional BCVA    soon as the first days after the 
  case series     injection. Such improvement  
       maintained until month 4
Boyer  DEX implant Randomised, FT DMO in 26 weeks 315 Both FT and BCVA improved from 
CHAMPLAIN for DMO controlled, BCVA vitrectomised   baseline by 1 week after treatment 
Study Group  multicentre,  eyes   with a DEX implant. Improvement 
201141  double-masked     remained statistically significant 
       throughout the 26-week study. The 
       peak effectiveness of DEX implants  
       was seen at week 8 to week 13
Haller DEX implant  BCVA Persistent 6 months 171 DEX implant of 700 μg produced 
201040 (700 μg or  FT MO   significant improvement in BCVA, 
 350 μg) for DMO  Fluorescein ≥90 days   FT and fluorescein leakage 
   leakage despite   compared with observation 
    treatment)   (statistically significant at day 90)
Kuppermann DEX implant  BCVA Persistent 6 months 315 At day 90 (primary end point), an 
200746  (700 μg or   FT MO   improvement in BCVA of 10 letters 
 350 μg) for  Fluorescein (≥90 days   or more was achieved by a greater 
 patients with  leakage despite   proportion of patients treated with 
 DMO, vein   treatment)   DEX implant, 700 μg (35%) or 
 occlusion,      350 μg (24 %). An improvement in 
 uveitis or      BCVA of 15 letters or more was 
 Irvine-Gass      achieved in 18 % of patients 
 syndrome MO      treated with DEX implant, 700 μg, 
       versus 6 % of observed patients
BCVA = best corrected visual acuity; DEX = dexamethasone intravitreal; DMO = diabetic macular oedema; FT= foveal thickness. Refractory MO = refractory DMO was  
defined as persistent MO with FT more than 250 μm by spectral-domain optical coherence tomography (OCT), lasting for at least 90 days after laser or intravitreal anti-vascular 
endothelial growth (VEGF)/steroid treatment.
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cortisol.65 A single dose of 0.18 mg/ml dexamethasone is equivalent to 
1 mg/ml triamcinolone in terms of corticosteroid efficacy and is short-
acting, with faster clearance from the vitreous.66 As stated above, an 
intravitreal implant that provides controlled, prolonged release of a 
drug may reduce the need for systemic drug administration or reduce 
the frequency of required ocular injections. In the DEX implant, the 
active drug is dispersed through a biodegradable copolymer of lactic 
acid and glycolic acid (PLGA), forming a matrix structure (Novadur®, 
Allergan Inc).67 These polymers have been used in a number of 
products, including absorbable sutures.68,69 For several years, PLGA has 
been used to prepare nanoparticles and microparticles for intraocular 
drug delivery. These drug delivery systems have been tested in animal 
models and humans.70–73
Experience has shown that PLGA is biocompatible and, inside the eye, 
is metabolised into carbon dioxide and water. Thus, sequential implants 
can be placed in an office setting without the need for surgical removal.74
A study in monkeys demonstrated that DEX is present at measurable 
levels in the vitreous and retina up to 6 months after intravitreal DEX 
implant injection.42 The implant is made of a solid biodegradable 
polymer that enables dual-phase pharmacokinetics. Ozurdex allows 
sustained delivery of dexamethasone to the vitreous cavity, initially 
releasing a burst of dexamethasone to rapidly achieve a therapeutic 
concentration followed by a lower sustained release. In the first phase, 
the concentration of DEX in both tissues was high from 7 days to 2 
months after placement of the implant, with the peak concentration 
of DEX achieved in the retina at two months. In the second phase, the 
concentration of DEX in both tissues was lower and slowly declined 
from three to six months after placement of the implant.42 This biphasic 
pharmacokinetic profile resembles that obtained with the systemic 
pulse administration of corticosteroids and is consistent with the 
sustained duration of action of DEX implant seen in clinical studies. 
Diffusion of substances in the vitreous is increased in eyes that have 
undergone vitrectomy.41 This may have beneficial effects in facilitating 
the removal of inflammatory mediators from the retina, but it also 
leads to more rapid clearance of some drugs, including triamcinolone 
acetonide (TA), from the vitreous, and may limit the effectiveness of 
these drugs in vitrectomised eyes. 
In the early clinical studies, the DEX implant was surgically implanted into 
the vitreous cavity via a pars plana incision.40,46 Subsequently, a single-
use, sutureless dexamethasone posterior-segment drug-delivery system 
(DDS) applicator was developed, allowing injection of the DEX implant in 
the office, rather than in a surgical setting.64 
Clinical Studies 
Comparison Between Two Doses of 
Dexamethasone Intravitreal Implant
Kuppermann et al. evaluated the efficacy and safety of two doses of 
DEX implant in the treatment of persistent ME of various aetiologies, 
in a 6-month, multicentre, randomised clinical phase II study.46 The 
315 patients in the trial had persistent MO due to either DR (n=172), 
RVO (n=102), Irvine-Gass syndrome (n=27), or uveitis (n=14). In each 
patient, one eye was randomised to treatment with 350 µg versus 
700 µg versus observation.
Implantation resulted in a statistically significant increase in patients 
gaining two and three lines or more of visual acuity in a dose-dependent 
fashion at 90 and 180 days compared with observation (p<0.025). The 
percentages of patients who gained two or more lines of visual acuity 
180 days after implantation were 32.4 % in the 700 µg group, 24.3 % 
in the 350 µg group and 21 % in the observation group (p=0.06). The 
percentages of patients who gained three or more lines of visual acuity 
180 days after implantation were 18.1 % in the 700 µg group, 14.6 % in the 
350 µg group and 7.6 % in the observation group (p=0.02). The visual 
acuity improvements achieved with the 700 µg implant were consistent 
across all subgroups at day 90.
In this sample, the DEX implant was well tolerated and had a favourable 
safety profile. The incidence of a ≥10 mmHg increase in intraocular 
pressure (IOP) from baseline was 3  % in the observation group, 
12 % in the 0.35 mg dexamethasone implant group and 17 % in the 
0.7 mg dexamethasone implant group. No significant between-group 
differences were found in the number of reports of cataract. However, 
treatment-related cataract formation may take longer than 180 days to 
become apparent.
Subgroup analysis of results in the patients with DMO showed that best 
corrected visual acuity (BCVA) improved more in patients treated with 
DEX implant than in untreated patients. Haller et al.40 demonstrated 
that, in eyes with DMO treated with dexamethasone intravitreal drug 
delivery 0.7 mg, BCVA and foveal thickness (FT) significantly improved 
at 3 months compared with the observation group. Interestingly, 
they found that BCVA improvement was no longer significant at 6 
months. Unfortunately, this randomised trial did not investigate the 
corresponding change in FT at the same time-point. Interestingly, in the 
subset of patients with DMO, an improvement in BCVA of ≥10 letters 
at day 90 was observed in 33.3 % of patients treated with the 0.7 mg 
DEX implant compared with 12.3  % of patients in the observation 
group. Among patients with diabetes, this significant difference was 
maintained when patients were stratified according to their pattern of 
DMO, i.e. focal, diffuse, cystoid and both cystoid and diffuse.75 Overall, 
the pattern of adverse events seen in these subpopulations was 
similar to that seen in the overall population of patients included in 
the phase II study.
Phase III randomised, multicentre, 3-year clinical studies to evaluate 
the long-term efficacy and safety of DEX implant in the treatment of 
DMO are ongoing.76
Comparison Between Vitrectomised versus  
Non-vitrectomised Patients
Pars plana vitrectomy (PPV) has been shown to be useful in the 
treatment of DMO in some patients.41–44 The mechanism for the effect 
of vitrectomy on DMO may involve both the release of vitreomacular 
traction and increased diffusion of advanced glycation end products, 
VEGF and other cytokines away from the retina.41,44 These findings 
suggest that sustained drug delivery with an implant could be 
particularly useful in vitrectomised eyes, thus enhancing and boosting 
the primary effect of vitrectomy. 
PPV has also been shown to affect the intraocular concentration of TA 
after intravitreal injection in human eyes.77,78 In a vitrectomised eye, the 
vitreous would be removed, and less-viscous liquid would fill the space, 
increasing intravitreal circulation. This pathophysiological process leads 
to a much faster corticosteroid absorption in the vitrectomised eye 
than in the normal eye. An implant that provides sustained drug release 
and is both safe and effective may be the best option for therapy. 
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Moreover, Chang-Lin et al. performed an earlier preclinical study 
examining the release of DEX from the DEX implant in a more-recent 
study was similar between non-vitrectomised and vitrectomised 
eyes in rabbit eyes.44 These results suggest that DEX implants may 
be particularly useful in the treatment of inflammation and MO in 
vitrectomised eyes. 
Boyer et al. undertook a prospective open-label study that assessed 
the efficacy and safety of the DEX implant in the treatment of chronic 
DMO in 56 patients with a history of PPV. In most cases, previous 
treatment had been attempted and had failed to resolve the DMO.41 
This trial in postvitrectomised eyes with persistent DMO (the 
CHAMPLAIN trial) was a 26-week open-label single Ozurdex injection 
trial. The study showed that 30 % of eyes had experienced a two-line 
improvement in BCVA by 13 weeks, although this effect diminished by 
the study endpoint of 26 weeks. 
The peak effectiveness of the DEX implant was seen between 8 
and 13  weeks after the injection. In this study, the efficacy of the 
DEX implant in reducing retinal thickness and improving BCVA in 
vitrectomised patients with DMO was similar to that seen in the 
subgroup of patients with DMO in the phase II study.40 Actually, the DEX 
implant may be especially beneficial in the treatment of inflammation 
and ME in difficult-to-treat vitrectomised eyes.
Dexamethasone Intravitreal Implant 
as a Combination Therapy with Laser 
Photocoagulation
The DEX implant was also investigated as a combination therapy with 
laser photocoagulation in DMO patients in the PLACID trial.79 The goal of 
the study was to evaluate the DEX implant 0.7 mg, combined with laser 
photocoagulation compared with laser alone for treatment of diffuse 
DMO. For this trial, 253 patients with retinal thickening and impaired 
vision resulting from diffuse DMO in at least one eye (the study eye) 
were enrolled.
Patients were randomised to treatment in the study eye with DEX implant 
at baseline, plus laser, at month 1 (combination treatment; n=26) or sham 
implant at baseline and laser at month 1 (laser alone; n=127). They could 
also receive up to three additional laser treatments and one additional 
DEX implant or sham treatment as needed.
The percentage of patients who gained 10 letters or more in BCVA at 
month 12 did not differ between treatment groups, but the percentage 
of patients was significantly greater in the combination group at 
month  1 (p<0.001) and month 9 (p=0.007). Increased IOP was more 
common with combination treatment. No surgeries for elevated IOP 
were required.
There was no significant between-group difference at month 12. 
However, significantly greater improvement in BCVA, as demonstrated 
by changes from baseline at various time-points up to 9 months, and 
across time based on the area under the curve analysis, occurred in 
patients with diffuse DMO treated with DEX implant, plus laser, than 
in patients treated with laser alone.
Interventional Case Series Studies 
Most recently, four interventional case series studies evaluated the 
efficacy of a dexamethasone intravitreous drug-delivery system in 
persistent ME secondary to diabetes.80–85 
In the first study, Zucchiatti et al.80 showed that a single intravitreal 
injection of Ozurdex produced improvement in BCVA and FT in eyes 
with persistent DMO. Such improvement was evident from the third 
day to the first month after injection, peaked at the third month and 
was no more significant 6 months after the injection. 
Analogously, Rishi et al.81 undertook another retrospective study, enrolling 
18 patients with refractory DMO. All patients experienced a significant 
reduction in FT compared with baseline levels at month 1. The maximum 
reduction in FT was seen at month 1, followed by reappearance of 
clinically significant MO at month 4. The peak effect of the drug was 
between 1 and 4 months. 
In 2013, Pacella et al. performed a prospective interventional case 
series to assess the efficacy of DEX implant in patients with 
persistent DMO over a 6-month follow-up period.82 Seventeen patients 
(20 eyes) affected by DMO were selected. Thirteen patients had 
also previously been treated with anti-VEGF medication. Ozurdex 
produced substantial improvement in BCVA and significant reduction 
of FT from day 3. The peak efficacy of the implant appears to be 
reached at month 1 through to month 3, then slowly decreases from 
month 4 to 6.
Similarly, we performed a retrospective interventional case series 
study to evaluate the effectiveness of a single intravitreal injection 
of Ozurdex, over 6 months in 58 patients with diabetes with 
persistent DMO.83 The patient population included severe cases that 
had not responded to multiple previous therapies. Both mean FT and 
mean BCVA had improved from baseline by 1 month after treatment 
with a DEX implant, and the improvement remained statistically 
significant throughout the 6-month study. The peak effectiveness 
of DEX implants was seen at 3 months after injection when mean 
FT had decreased by 37 %. The mean BCVA improved to 0.44±0.27 
logMAR from baseline. Our data were consistent with those results 
named previously.
Twenty-four patients had undergone PPV before entering in our sample. 
The improvement in FT and BCVA seen in this sample was similar 
to the improvement seen in the remaining non-vitrectomised patients 
with persistent MO. Our data were consistent with those from a recent 
analysis of the earlier publications addressing this matter.41 
To our knowledge, there have been no differences on the relative 
effectiveness of dexamethasone implants in pseudophakic versus 
phakic eyes. Further studies will be needed to determine whether the 
effects of dexamethasone implants are affected by lens status.
The target population addressed in our trial was difficult to treat because 
it included severe cases of long-standing DMO that had failed to 
respond to therapy with PPV, focal laser and/or pharmacotherapy, (most 
commonly intravitreal injection of the corticosteroid TA or the anti-VEGF 
therapy). In fact, one-third of the patients had previously undergone 
triple therapy. In these cases, the potential for improvement in vision 
was likely limited by secondary functional and structural changes related 
to chronic oedema.
Conclusion 
The treatment of DMO has evolved to encompass a combination of 
multi-target therapeutic approaches. In recent decades, corticosteroids 
have raised interest in the treatment of DMO due to their anti-
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Erratum 
The authors would like to make the following adjustment to the above mentioned article. 
On page 68 and in the section titled “Iluvien” the sentence “Due its non-biodegradability, it is necessary to surgically remove the implant 
3 years later” should be amended to “The implant does not need to be surgically removed once implanted.”
